Literature DB >> 12928771

Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients.

M Saraheimo1, A-M Teppo, C Forsblom, J Fagerudd, P-H Groop.   

Abstract

AIMS/HYPOTHESIS: Increased concentrations of C-reactive protein and interleukin-6, a finding suggestive of the presence of inflammation, have been observed in Type 2 diabetes. In such patients, C-reactive protein was predictive of diabetic nephropathy. Studies on low-grade inflammatory markers and nephropathy in Type 1 diabetic patients have shown conflicting results. Therefore we studied whether low-grade inflammation is associated with diabetic nephropathy in Type 1 diabetic patients.
METHODS: We divided 194 Type 1 diabetic patients into three groups from the Finnish Diabetic Nephropathy Study based upon their albumin excretion rate. Patients with normoalbuminuria (n=67) had no antihypertensive medication or signs of cardiovascular disease, while patients with microalbuminuria (n=64) or macroalbuminuria (n=63) were all treated with an angiotensin-converting enzyme inhibitor, a drug that could attenuate low-grade inflammation. As a measure of insulin sensitivity we used estimated glucose disposal rate. C-reactive protein was measured by radioimmunoassay and interleukin-6 by high sensitivity enzyme immunoassay.
RESULTS: C-reactive protein was higher in micro- and macroalbuminuric patients compared to normoalbuminuric patients (normoalbuminuria 2.0+/-1.7, microalbuminuria 2.6+/-1.7, macroalbuminuria 2.9+/-2.5 mg/l; p=0.016), while interleukin-6 increased in parallel with the severity of the renal disease (1.9+/-1.5, 2.9+/-3.3, 3.6+/-3.1 ng/l; p<0.0001). In multiple regression analysis albumin excretion rate was the only variable independently associated with C-reactive protein (p=0.03), whereas albumin excretion rate (p=0.0003), HDL-cholesterol (p=0.0135) and duration of diabetes (p=0.0176) were independently associated with interleukin-6. CONCLUSIONS/
INTERPRETATION: Low-grade inflammatory markers are associated with diabetic nephropathy in Type 1 diabetic patients. The predictive value needs to be assessed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12928771     DOI: 10.1007/s00125-003-1194-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  23 in total

1.  Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy.

Authors:  M Shikano; H Sobajima; H Yoshikawa; T Toba; H Kushimoto; H Katsumata; M Tomita; S Kawashima
Journal:  Nephron       Date:  2000-05       Impact factor: 2.847

2.  Can clinical factors estimate insulin resistance in type 1 diabetes?

Authors:  K V Williams; J R Erbey; D Becker; S Arslanian; T J Orchard
Journal:  Diabetes       Date:  2000-04       Impact factor: 9.461

3.  Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation.

Authors:  C G Schalkwijk; D C Poland; W van Dijk; A Kok; J J Emeis; A M Dräger; A Doni; V W van Hinsbergh; C D Stehouwer
Journal:  Diabetologia       Date:  1999-03       Impact factor: 10.122

4.  Interleukin-6 induces cellular insulin resistance in hepatocytes.

Authors:  Joseph J Senn; Peter J Klover; Irena A Nowak; Robert A Mooney
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.

Authors:  V Mohamed-Ali; S Goodrick; A Rawesh; D R Katz; J M Miles; J S Yudkin; S Klein; S W Coppack
Journal:  J Clin Endocrinol Metab       Date:  1997-12       Impact factor: 5.958

7.  Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study.

Authors:  Trevor J Orchard; Yue-Fang Chang; Robert E Ferrell; Nancy Petro; Demetrius E Ellis
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

8.  The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus.

Authors:  K Borch-Johnsen; P K Andersen; T Deckert
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

Review 9.  Muscle-derived interleukin-6: possible biological effects.

Authors:  B K Pedersen; A Steensberg; P Schjerling
Journal:  J Physiol       Date:  2001-10-15       Impact factor: 5.182

Review 10.  Transcription factor-kappa B (NF-kappa B) and renal disease.

Authors:  C Guijarro; J Egido
Journal:  Kidney Int       Date:  2001-02       Impact factor: 10.612

View more
  82 in total

1.  The effects of anti-inflammatory and anti-angiogenic DNA vaccination on diabetic nephropathy in rats.

Authors:  Peter Celec; Július Hodosy; Roman Gardlík; Michal Behuliak; Roland Pálffy; Marek Pribula; Peter Jáni; Ján Turňa; Katarína Sebeková
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

Review 2.  Microvascular disease in children and adolescents with type 1 diabetes and obesity.

Authors:  M Loredana Marcovecchio; Francesco Chiarelli
Journal:  Pediatr Nephrol       Date:  2010-08-19       Impact factor: 3.714

3.  Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum.

Authors:  Ville-Petteri Mäkinen; Pasi Soininen; Carol Forsblom; Maija Parkkonen; Petri Ingman; Kimmo Kaski; Per-Henrik Groop; Mika Ala-Korpela
Journal:  MAGMA       Date:  2006-12-15       Impact factor: 2.310

4.  Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study.

Authors:  S Araki; M Haneda; D Koya; T Sugimoto; K Isshiki; M Chin-Kanasaki; T Uzu; A Kashiwagi
Journal:  Diabetologia       Date:  2007-01-16       Impact factor: 10.122

5.  Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy.

Authors:  M Saraheimo; C Forsblom; T K Hansen; A-M Teppo; J Fagerudd; K Pettersson-Fernholm; S Thiel; L Tarnow; P Ebeling; A Flyvbjerg; P-H Groop
Journal:  Diabetologia       Date:  2004-12-23       Impact factor: 10.122

6.  Leisure-time physical activity and development and progression of diabetic nephropathy in type 1 diabetes: the FinnDiane Study.

Authors:  Johan Wadén; Heidi K Tikkanen; Carol Forsblom; Valma Harjutsalo; Lena M Thorn; Markku Saraheimo; Nina Tolonen; Milla Rosengård-Bärlund; Daniel Gordin; Heikki O Tikkanen; Per-Henrik Groop
Journal:  Diabetologia       Date:  2015-01-30       Impact factor: 10.122

7.  Data-driven metabolic subtypes predict future adverse events in individuals with type 1 diabetes.

Authors:  Raija Lithovius; Iiro Toppila; Valma Harjutsalo; Carol Forsblom; Per-Henrik Groop; Ville-Petteri Mäkinen
Journal:  Diabetologia       Date:  2017-04-24       Impact factor: 10.122

8.  Elevated MBL concentrations are not an indication of association between the MBL2 gene and type 1 diabetes or diabetic nephropathy.

Authors:  Mari A Kaunisto; Lisa Sjölind; Riitta Sallinen; Kim Pettersson-Fernholm; Markku Saraheimo; Sara Fröjdö; Carol Forsblom; Johan Fagerudd; Troels K Hansen; Allan Flyvbjerg; Maija Wessman; Per-Henrik Groop
Journal:  Diabetes       Date:  2009-04-14       Impact factor: 9.461

9.  Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes.

Authors:  Mariann Nymark; Pirkko J Pussinen; Anita M Tuomainen; Carol Forsblom; Per-Henrik Groop; Markku Lehto
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 19.112

10.  The relation of C--reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study.

Authors:  Ervin R Fox; Emelia J Benjamin; Daniel F Sarpong; Harsha Nagarajarao; Jason K Taylor; Michael W Steffes; Abdullah K Salahudeen; Michael F Flessner; Ermeg L Akylbekova; Caroline S Fox; Robert J Garrison; Herman A Taylor
Journal:  BMC Nephrol       Date:  2010-01-15       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.